Responses
Regular and Young Investigator Award Abstracts
Cell Therapies
197 Preliminary safety and efficacy of autologous anti-MSLN T cell engager-loaded T cells (CAB-T) in patients with mesothelin-expressing advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.